HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 5, 2004, Pages 398-406

  Palumbo, Camilla ^a   Albonici, Loredana ^a   Bei, Roberto ^a   Bocci, Chiara ^a   Scarpa, Susanna ^b   Di Nardo, Paolo ^a   Modesti, Andrea ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Doxorubicin; Drug synergism; HMBA; Intrapleural chemotherapy; Mesothelioma

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; HEXAMETHYLENEBISACETAMIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; METASTASIS; NICK END LABELING; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; TOXICITY; WESTERN BLOTTING;

ACETAMIDES; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; HUMANS; MESOTHELIOMA; RNA, NEOPLASM;

EID: 7744228107     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0838-6     Document Type: Article

References (39)

1. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA (1992) Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80:2604-2609
2. Antman KH, Schiff PB, Pass HI (1997) Benign and malignant mesothelioma. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 1853-1878
3. Attanoos RL, Gibbs AR (1997) Pathology of malignant mesothelioma. Histopathology 30:403-418
4. Bill CA, Vines CM, Garrett KC, Yamada K, Tofilon PJ (1990) Enhancement of the radiosensitivity of two human tumor cell lines by hexamethylene bisacetamide. Br J Cancer 61:563-567
5. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A (2001) Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 159:721-731
6. Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A, Van Echo DA (1992) Approaches to optimal dosing of hexamethylene bisacetamide. Cancer Chemother Pharmacol 31:37-45
7. + increases mitochondrial NO and Bax protein. J Neurosci Res 79:76-88
8. 2 adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice. Pain 84:13-20
9. Gewirtz DA (1999) A critical evaluation of the mechanism of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741
10. Greco WR, Bravo G, Parson JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331-385
11. Gross A, McDonnell JM, Korsemeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911
12. Guilbaud NF, Gas N, Dupont MA, Valette A (1990) Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 145:162-172
13. Howard S, Bottino C, Brooke S, Cheng E, Giffard RG, Sapolsky R (2002) Neuroprotective effect of bcl-2 overexpression in hippocampal cultures: interactions with pathways of oxidative damage. J Neurochem 83:914-923
14. Isobe H, Wellham L, Sauerteig A, Sridar KS, Ramachandran C, Krishan A (1994) Doxorubicin retention and chemoresistance in human mesothelioma cell lines. Int J Cancer 57:581-585
15. Kern DH, Morgan CR, Hildebrand-Zanki SU (1988) In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 48:117-121
16. Khan MZ, Freshney RI, McNicol AM, Murray AM (1993) Induction of phenotypic changes in SCLC cell lines in vitro by hexamethylene bisacetamide, sodium butyrate, and cyclic AMP. Ann Oncol 4:499-507
17. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R, Mertelsmann R (1991) Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49:630-637
18. Marks PA, Richon VM, Kiyokawa H, Rifkind RA (1994) Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci U S A 91:10251-10254
19. Mercatante DR, Bortner CD, Cidlowsky JA, Kole R (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. J Biol Chem 278:16411-16417
20. Bax. J Biol Chem 270:26049-26052
21. Ogretmen B, Bahadori HR, McCauley MD, Boylan A, Green MR, Safa AR (1998) Co-ordinated over-expression of the MRP and γ-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines. Int J Cancer 75:757-761
22. Rajagopalan S, Rodrigues M, Polk T, Wilson D, Chader GJ, Hayden BJ (1993) Modulation of retinoblastoma cell characteristics by hexamethylene bis-acetamide and other differentiating agents in culture. J Histochem Cytochem 41:1331-1337
23. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 93:5705-5708
24. Rihn BH, Mohr S, McDowell SA, Binet S, Loubinoux J, Galateau F, Keith G, Leikauf GD (2000) Differential gene expression in mesothelioma. FEBS Lett 480:95-100
25. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F (1998) In vitro and in vivo interaction between cis-platin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41:385-390
26. Ruefli AA, Smyth MJ, Johnstone RW (2000) HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 95:2378-2385
27. Scarpa S, Giuffrida A, Fazi M, Coletti A, Palumbo C, Pass HI, Procopio A, Modesti A (1999) Migration of mesothelioma cells correlates with histotype-specific synthesis of extracellular matrix. Int J Mol Med 4:67-71
28. Schroy PC, Rustgi AK, Ikonomu E, Liu XP, Polito J, Andry C, O'Keane JC (1994) Growth and intestinal differentiation are independently regulated in HT29 colon cancer cells. J Cell Physiol 161:111-123
29. L determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene 18:5703-5713
30. Siegel DS, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon VM, Rifkind RA, Marks PA, Michaeli J (1998) Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc Natl Acad Sci U S A 95:162-166
31. Smythe WR, Mohuiddin I, Ozveran M, Cao XX (2002) Anti-sense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 123:1191-1198
32. Soini Y, Jarvinen K, Kaarteenaho-Wiik R, Kinnula V (2001) The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12:1239-1245
33. Sterman DH, Kaiser LR, Albelda SM (1999) Advances in the treatment of malignant pleural mesothelioma. Chest 116:504-520
34. Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti G, Zoli W (2002) In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 8:233-239
35. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL (1999) Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5:1587-1594
36. Ward FT, Kelley JA, Roth JS, Lombardo FA, Weiss RB, Leyland-Jones B, Chun HG (1991) A phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube. Cancer Res 51:1803-1810
37. Waxman S, Scher BM, Hellinger N, Scher W (1990) Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res 50:3878-3887
38. Young CW, Fanucchi MP, Walsh TD, Baltzer L, Yaldaei S, Stevens Y, Gordon C, Tong W, Rifkind RA, Marks PA (1988) Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res 48:7304-7309
39. Zellos LS, Sugarbaker DJ (2002) Multimodality treatment of diffuse malignant mesothelioma. Semin Oncol 29:41-50